Updated trends in US brand-name and generic drug competition

Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives

1. High dose therapy and autologous and allogeneic stem cell rescue for hematologic malignancies (especially multiple myeloma) and solid tumors. 2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors. 3. Supportive care for hematopoietic stem cell transplants. 4. Prevention and therapy of graft versus host disease.